A major difference between hormone receptor-positive and hormone receptor-negative patients is that HRPBC patients, which composes about 70% of all breast cancer cases, uniformly receive tamoxifen as standard adjuvant anti-hormone therapy, which hormone receptor-negative patients do not receive [41, 42]. The gene discussed is NR4A1; the disease is breast carcinoma.